Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.
about
Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapyMonoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published EvidenceTreating children with inflammatory bowel disease: Current and new perspectives.Use of anti-TNF drug levels to optimise patient management.A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn's disease.Is there a reason for concern or is it just hype? - A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars.A Critical Review of Biosimilars in IBD: The Confluence of Biologic Drug Development, Regulatory Requirements, Clinical Outcomes, and Big Business.The biologics of ulcerative colitis.Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases.Switching from Remicade® to Remsima® is well Tolerated and Feasible: A Prospective, Open-label Study.Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassaysClinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease.Biosimilarity and Interchangeability: Principles and Evidence: A Systematic Review.Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts.The performance of Remicade®-optimized quantification assays in the assessment of Flixabi® levels
P2860
Q28067631-97EFE971-F5F1-4B52-97A6-DD13EEAF09E3Q28078423-935E0C27-55DB-4EE0-B0B0-B9E987626231Q38602911-44897D84-03B9-4AA9-9831-3152687D73B0Q38608951-6D590E2C-6A5C-42AA-8083-95B957EBFBD3Q38707864-7F07DB40-3E82-4524-ABC7-2B628198E165Q38708927-C1D35643-9155-44B5-8C6A-3F3FC7AAB755Q38937842-8B1F5D39-85C9-42DC-95A1-49A11C382E34Q39037681-1BB45430-DA90-49D2-AF75-115483985C75Q39152159-F32471DF-2EA0-4550-8821-B6BFA7872F0EQ39359495-648D70D2-5624-4A23-BD39-7A687965E494Q41078498-1839EF08-3E66-4BD0-983E-9CFFBE8E7A34Q48250204-8ECEC40B-4D5C-4CD7-AE69-CB1AA4AAE977Q49979586-B5BA4CAE-A771-45D8-A2F0-39DB8EB4E721Q55212098-5CEA99C1-449F-42C9-88B1-326C8BCE5BF0Q58701964-C8475580-B75E-4CCA-82F0-C79FA6195F96
P2860
Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Review article: pharmacologica ...... n inflammatory bowel diseases.
@en
type
label
Review article: pharmacologica ...... n inflammatory bowel diseases.
@en
prefLabel
Review article: pharmacologica ...... n inflammatory bowel diseases.
@en
P2093
P2860
P356
P1476
Review article: pharmacologica ...... n inflammatory bowel diseases.
@en
P2093
B G Levesque
K Papamichael
N Vande Casteele
S Vermeire
T Van Stappen
P2860
P304
P356
10.1111/APT.13402
P407
P577
2015-09-13T00:00:00Z